A seven-year Canadian study reveals that addiction treatment readmission is far more common than most people realise. More than two in five clients who moved from detoxification into residential care eventually returned for another episode. The findings, drawn from nearly 10,500 admissions in Alberta, raise urgent questions about what the system is getting wrong and who bears the cost.

The research appears in the American Journal on Addictions in 2026. It analysed records from 4,915 clients across Alberta’s publicly funded detox and residential treatment network between April 2015 and March 2022.

The Scale of Residential Treatment Readmission

Overall, 41.6% of clients, equating to 2,046 people, returned to residential treatment at least once. That group drove 72.6% of all admissions during the study period. They averaged 3.7 admissions per person.

A small cluster of very high-need individuals skewed the numbers further. Just 1.8% of the sample accumulated between 10 and 44 admissions each. That tiny group alone accounted for 12.3% of all treatment episodes.

Alberta ran five detox facilities with 116 beds and five residential centres with 174 beds during this period. Two urban sites handled nearly 80% of all admissions. The pressure on that limited capacity is obvious when you consider that readmitted clients consumed nearly three-quarters of all available treatment slots.

What Drugs and Alcohol Do to Addiction Treatment Readmission Rates

The substance someone used shaped their readmission risk in clear ways. People with opioid use disorder were 25% more likely to return to residential care. Those with alcohol use disorder faced 26% higher odds. Both findings surprised the researchers, given that Alberta already runs established withdrawal protocols and opioid agonist therapy programmes for both groups.

The study found that opioid agonist therapy, which includes buprenorphine, methadone and naltrexone, had reduced opioid-related deaths in the province. But it had not lowered addiction treatment readmission rates among opioid users. Pharmacotherapies for alcohol use disorder showed similarly mixed results on relapse and abstinence outcomes.

Cocaine told a different story. People whose main substance was cocaine were 22% less likely to experience residential treatment readmission. The researchers suggest cocaine produces less physically severe withdrawal symptoms than alcohol or opioids, which makes it easier for people to stay in and complete treatment.

Using more than one substance at once increased the risk further. People with polysubstance use were nearly twice as likely to be readmitted as those dealing with a single substance.

Who Faces the Highest Risk of Returning to Treatment

Instability in daily life proved to be a stronger predictor than any fixed social status. People in unstable employment, meaning those who moved between jobs and unemployment during the study period, faced nearly three times the odds of addiction treatment readmission (OR = 2.96). Their raw readmission rate was 77.3%. By comparison, people who stayed consistently unemployed had a 43% rate, and those who remained employed throughout had just 36%.

Shifting marital status carried similar weight. People whose relationship status changed during the study, whether through separation, divorce or remarriage, had more than two and a half times the odds of residential treatment readmission compared to those who stayed unmarried. Relationship instability and addiction appear to reinforce each other in ways that increase relapse risk over time.

Geography played its part too. People who moved between urban and rural areas faced nearly double the odds of readmission compared to those who stayed rural. Greater mobility gave these individuals access to multiple detox facilities, and using multiple facilities itself raised their risk further.

Addiction Treatment Readmission and Detox Completion Patterns

Some of the most striking findings came not from who the clients were, but from how they engaged with services.

People who did not complete their detox programme faced 5.5 times the odds of residential treatment readmission compared to completers. But the highest-risk group were those who alternated between completing and not completing detox across different admissions. Their odds of readmission were nearly 12 times higher (OR = 11.84). The pattern suggests that inconsistent engagement with detox is one of the clearest warning signs available.

How Transition Timing Shapes Residential Treatment Readmission

Timing between detox discharge and entry into residential care turned out to matter enormously. People who moved within 14 days were far less likely to return for additional treatment. Those who waited longer than 14 days faced odds more than 13 times higher (OR = 13.45).

That single finding may be the most practically useful in the entire study. Reducing the gap between detox and residential placement does not require changing who someone is. It requires changing how services are coordinated.

Facility type also shaped outcomes. Clients who left detox centres co-located with residential treatment programmes had lower readmission rates, between 28.1% and 29.0%, compared to 30% to 43% at stand-alone sites. Sticking to a single facility throughout care, rather than moving across multiple sites, cut the odds of readmission by half.

What the Data Really Tell Us About the System

The evidence here does not point to a failure of willpower or motivation. It points to a failure of coordination. System design, transition speed, facility integration and social stability all independently shape whether someone returns for more treatment.

The authors call for targeted support for people with alcohol or opioid use disorders, unstable employment, relationship instability or a history of not completing detox. They also highlight co-located detox and residential services as a structural fix that reduces residential treatment readmission without requiring individuals to do anything differently.

Reducing the wait between detox discharge and residential placement could have outsized impact. So could social support programmes that address job insecurity and relationship breakdown alongside substance use treatment. For a group where the readmission rate reaches 77%, economic and relational stability clearly matter as much as clinical care.

Did COVID Change the Numbers?

Clients admitted between 2019 and 2022 showed lower odds of addiction treatment readmission than earlier cohorts. The readmission rate dropped from 45% pre-pandemic to 38.7% during the COVID period, a statistically significant shift. The researchers attribute this to service disruptions, shifting government priorities and changes in how resources were allocated, rather than any real improvement in recovery outcomes.

What the Study Cannot Tell Us

The research relies on administrative data. It captures system activity accurately, but it cannot capture what clients actually experienced. It also covers only publicly funded provincial services, leaving out community-based and private programmes.

Canada’s universal public healthcare model also limits how directly these findings apply elsewhere. Countries running mixed public and private insurance systems for addiction treatment may see different patterns.

The study confirms that opioid agonist therapy was available to clients, but detailed prescribing data were not accessible. Future research linking treatment records with OAT medication data could shed more light on how pharmacological support interacts with residential treatment readmission over the long term.

Source: dbrecoveryresources